Astrotech Corp. (NASDAQ: ASTC) Subsidiary, “1st Detect”, Focuses on Superior Narcotics Trace Detection For Airport and Other Security Sites

• Astrotech Corporation Subsidiary 1st Detect Approved as GSA Vendor; Introduces Advanced Narcotics Trace Detection Technology
• 1st Detect has now received approval from the U.S. General Services Administration (“GSA”) as an authorized vendor for government-related applications
• 1st Detect recently introduced a state-of-the-art Narcotics Trace Detection (“NTD”) narcotics library, which is particularly useful for detection at points of entry and government agencies involved in combating the illicit drug trade
• 1st Detect’s portfolio now includes the TRACER 1000, Explosives Trace Detection (“ETD”) and Narcotics Trace detection

Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. With recent approval as a U.S. General Services Administration (“GSA”) authorized vendor, 1st Detect is poised to expand its impact across government agencies. TRACER 1000, a cutting-edge detector utilizing ruggedized mass spectrometry technology for superior detection at critical security points. 1st Detect’s commitment to excellence is underscored by its recent achievements and milestones, including its approval by the U.S. General Services Administration as an authorized vendor for key government-related applications (https://ibn.fm/EdwZq). This opens doors to 1st Detect’s products to a wide array of opportunities within government agencies tasked with ensuring national security.

At the heart of 1st Detect’s portfolio lies the TRACER 1000, a cutting-edge trace detector leveraging ruggedized mass spectrometry technology. This instrument represents the pinnacle of innovation in both ETD and now NTD, offering unmatched performance and versatility for security screening applications (https://ibn.fm/S1M7x).

Key features of the TRACER 1000:

• Ruggedized mass spectrometry technology
• Simple to use interface
• Seamless integration of new narcotics libraries

This development is particularly crucial for airport security and government agencies involved in combating the illicit drug trade by making updates for new drug profiles easy. By incorporating such advancements in mass spectrometry technology widely regarded as the “gold standard” in the industry, Astrotech has set a new standard for accuracy and reliability in narcotics detection.

Astrotech’s commitment to innovation and excellence was on full display at the recent ISC West Conference, held in April in Las Vegas. As a premier event focusing on security and public safety, ISC West provided an ideal platform for Astrotech to showcase its TRACER 1000 trace detector to industry professionals and decision-makers (https://ibn.fm/CHToD). The company’s participation underscores its dedication to staying at the forefront of technological advancements and addressing the evolving needs of the security market.

Thomas B. Pickens, III, Astrotech’s CEO, and Chief Technology Officer, said: “We are very excited about introducing our narcotics detection library that includes twelve illegal drugs including fentanyl, heroin, and cocaine.”  On the occasion, Pickens also said the company was extremely excited to share its user-friendly mass spectrometer the TRACER 1000 with leading industry experts and security industry professionals at the ISC West conference. “This allows us a platform to reach those in the industry across various markets, such as security, checkpoint, military, and law enforcement that strive for quality instrumentation, that requires a minimum amount of maintenance, and want accurate but rapid detection.”

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN